AK104 in Neoadjuvant Treatment of Cervical Cancer
Phase II open label study to evaluate the safety and efficacy of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) in neoadjuvant treatment of cervical cancer.
Cervical Cancer
DRUG: AK104
Adverse Events (AEs), The number of participants experiencing an AE will be assessed. An AE is defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy., Up to approximately 6 mouths|Major pathological response (MPR) rate, MPR rate is defined as the percentage of participants having â‰¤ 10% viable tumor cells in the pathological examination of resected specimens., within 14 working days after operation
R0 resection rate, R0 resection rate is defined as the percentage of patients whose post-operative pathology indicate complete tumor resection with all margins being negative., within 14 working days after operation|Pathological Complete Response (pCR) rate, pCR rate is defined as the percentage of participants lacking of evidence of viable tumor cells in the pathological examination of resected specimens., within 14 working days after operation|Objective response rates (ORR), ORR is the proportion of subjects with complete response(CR) or partial response(PR) , based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1., 4-6 weeks after the first cycle of neoadjuvant treatment
Phase II open label study to evaluate the safety and efficacy of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) in neoadjuvant treatment of cervical cancer.